Novel avenues in immunotherapies for colorectal cancer

References

• Burnet FM. Cancer – a biological approach; I. The process of control. Br Med J. 1957;1(5022):779–786.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA. 1997;94(6):2545–2550.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf). 2015;3(4):269–276.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–2087, e2073.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3208–3215.
   PubMed Web of Science ®Google Scholar
• Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044–2058.
   PubMed Web of Science ®Google Scholar
• Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–268.
   PubMed Web of Science ®Google Scholar
• Maby P, Tougeron D, Hamieh M, et al. Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75(17):3446–3455.
   PubMed Web of Science ®Google Scholar
• Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91(12):2417–2422.
   PubMed Web of Science ®Google Scholar
• Ueno H, Hashiguchi Y, Shimazaki H, et al. Objective criteria for Crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol. 2013;139(4):434–441.
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–618.
   PubMed Web of Science ®Google Scholar
• Speetjens FM, Kuppen PJ, Morreau H, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;135(2):711–712; author reply 712–713.
   PubMed Web of Science ®Google Scholar
• Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. Clin Dev Immunol. 2010;2010:170432.
   PubMedGoogle Scholar
• Johnson CM, Wei C, Ensor JE, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24(6):1207–1222.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Shanahan F, O’Toole PW. Host-microbe interactions and spatial variation of cancer in the gut. Nat Rev Cancer. 2014;14(8):511–512.
   PubMed Web of Science ®Google Scholar
• Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. 2014;16(10):406.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–976.
   PubMed Web of Science ®Google Scholar
• Garaude J, Kent A, van Rooijen N, et al. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med. 2012;4(120):120ra116.
   Google Scholar
• Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of toll-like receptors in cancer. Oncogene. 2014;33(27):3485–3495.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–626.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu L, Zhang Q, et al. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. Biomed Pharmacother. 2014;68(6):715–720.
   PubMed Web of Science ®Google Scholar
• Hoover HC Jr, Surdyke M, Dangel RB, et al. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res. 1984;44(4):1671–1676.
   PubMed Web of Science ®Google Scholar
• Gray BN, Walker C, Andrewartha L, et al. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol. 1989;40(1):34–37.
   PubMed Web of Science ®Google Scholar
• Hoover HC Jr, Hanna MG Jr. Active immunotherapy in colorectal cancer. Semin Surg Oncol. 1989;5(6):436–440.
   PubMedGoogle Scholar
• Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–399.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353(9150):345–350.
   PubMed Web of Science ®Google Scholar
• Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18(1):148–157.
   PubMed Web of Science ®Google Scholar
• Baars A, Claessen AM, Wagstaff J, et al. A phase II study of active specific immunotherapy and 5-FU/leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer. 2002;86(8):1230–1234.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17–18):2379–2387.
   PubMed Web of Science ®Google Scholar
• Lehner B, Schlag P, Liebrich W, et al. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine. Cancer Immunol. 1990;32(3):173–178.
   Google Scholar
• Schlag P, Manasterski M, Gerneth T, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol. 1992;35(5):325–330.
   Google Scholar
• Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2(1):21–28.
   PubMed Web of Science ®Google Scholar
• Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. 2009;58(1):61–69.
   Google Scholar
• Maxwell-Armstrong CA, Durrant LG, Robins RA, et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut. 1999;45(4):593–598.
   PubMed Web of Science ®Google Scholar
• Karanikas V, Thynne G, Mitchell P, et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother. 2001;24(2):172–183.
   Web of Science ®Google Scholar
• Moulton HM, Yoshihara PH, Mason DH, et al. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res. 2002;8(7):2044–2051.
   PubMed Web of Science ®Google Scholar
• Sato Y, Maeda Y, Shomura H, et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer. 2004;90(7):1334–1342.
   PubMed Web of Science ®Google Scholar
• Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. 2008;57(9):1413–1420.
   Google Scholar
• Speetjens FM, Kuppen PJ, Welters MJ, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. 2009;15(3):1086–1095.
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Torigoe T, et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 2011;102(6):1181–1187.
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Speetjens FM, Welters MJ, et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer. 2013;132(7):1581–1591.
   PubMed Web of Science ®Google Scholar
• Hazama S, Nakamura Y, Tanaka H, et al. A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014;12:108.
   PubMed Web of Science ®Google Scholar
• Rahma OE, Hamilton JM, Wojtowicz M, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55.
   PubMed Web of Science ®Google Scholar
• Rains N, Cannan RJ, Chen W, et al. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology. 2001;48(38):347–351.
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98(15):8809–8814.
   PubMed Web of Science ®Google Scholar
• Liu KJ, Wang CC, Chen LT, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004;10(8):2645–2651.
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11(8):3017–3024.
   PubMed Web of Science ®Google Scholar
• Babatz J, Rollig C, Lobel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. 2006;55(3):268–276.
   Google Scholar
• Burgdorf SK, Fischer A, Claesson MH, et al. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res. 2006;25(2):201–206.
   PubMed Web of Science ®Google Scholar
• Kavanagh B, Ko A, Venook A, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunotherapy. 2007;30(7):762–772.
   PubMed Web of Science ®Google Scholar
• Barth RJ Jr, Fisher DA, Wallace PK, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16(22):5548–5556.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, De Vries IJ, Schreibelt G, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010;30(12):5091–5097.
   PubMed Web of Science ®Google Scholar
• Sakakibara M, Kanto T, Hayakawa M, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol. 2011;60(11):1565–1575.
   Google Scholar
• Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013;258(6):879–886.
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang X, Li J, et al. Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int. 2014;2014:603871.
   PubMed Web of Science ®Google Scholar
• Gao D, Li C, Xie X, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. Plos One. 2014;9(4):e93886.
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12(11 Pt 1):3416–3424.
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4487–4494.
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. 2008;57(7):977–986.
   Google Scholar
• Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunotherapy. 2008;31(9):820–829.
   PubMed Web of Science ®Google Scholar
• Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. 2013;62(8):1293–1301.
   Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23(35):8968–8977.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control. 2013;20(4):289–297.
   PubMed Web of Science ®Google Scholar
• Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy. Discov Med. 2013;15(84):301–308.
   PubMed Web of Science ®Google Scholar
• Hanna MG Jr, Hoover HC Jr, Pinedo HM, et al. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological Pharmacodynamics. Hum Vaccin. 2006;2(4):185–191.
   PubMed Web of Science ®Google Scholar
• Matsushita N, Aruga A, Inoue Y, et al. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep. 2013;29(3):951–959.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48.
   PubMed Web of Science ®Google Scholar
• Koido S, Ohkusa T, Homma S, et al. Immunotherapy for colorectal cancer. W J Gastroenterol. 2013;19(46):8531–8542.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002;9(2):202–208.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148.
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
   PubMed Web of Science ®Google Scholar
• von Boehmer L, Mattle M, Bode P, et al. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immun. 2013;13:12.
   PubMedGoogle Scholar
• Pernot S, Terme M, Voron T, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. 2014;20(14):3738–3750.
   PubMed Web of Science ®Google Scholar
• Menon AG, Morreau H, Tollenaar RA, et al. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest. 2002;82(12):1725–1733.
   PubMed Web of Science ®Google Scholar
• Cabrera CM, Jimenez P, Cabrera T, et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens. 2003;61(3):211–219.
   PubMed Web of Science ®Google Scholar
• Speetjens FM, De Bruin EC, Morreau H, et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol. 2008;57(5):601–609.
   Google Scholar
• Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118(1):6–10.
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Van Hoesel AQ, Speetjens FM, et al. FoxP3- and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer. Cancer Microenviron. 2013;6(1):31–39.
   PubMedGoogle Scholar
• Curigliano G, Criscitiello C, Gelao L, et al. Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013;19(20):5564–5571.
   PubMed Web of Science ®Google Scholar
• Wieten L, Mahaweni NM, Voorter CE, et al. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens. 2014;84(6):523–535.
   PubMed Web of Science ®Google Scholar
• Levy EM, Bianchini M, Von Euw EM, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008;32(3):633–641.
   PubMed Web of Science ®Google Scholar
• Palmisano GL, Contardi E, Morabito A, et al. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005;66(1):1–12.
   PubMed Web of Science ®Google Scholar
• Benevolo M, Mottolese M, Tremante E, et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med. 2011;9:184.
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Reimers MS, Saadatmand S, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014;110(2):459–468.
   PubMed Web of Science ®Google Scholar
• Zhen ZJ, Ling JY, Cai Y, et al. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol. 2013;30(1):482.
   PubMed Web of Science ®Google Scholar
• Bossard C, Bezieau S, Matysiak-Budnik T, et al. HLA-E/beta2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer. 2012;131(4):855–863.
   PubMed Web of Science ®Google Scholar
• Guo ZY, Lv YG, Wang L, et al. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol. 2015;293(1):10–16.
   PubMed Web of Science ®Google Scholar
• Alegre E, Rizzo R, Bortolotti D, et al. Some basic aspects of HLA-G biology. J Immunol Res. 2014;2014:657625.
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, LeMaoult J, et al. The dual role of HLA-G in cancer. J Immunol Res. 2014;2014:359748.
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, Ferrone S, et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005;65(22):10139–10144.
   PubMed Web of Science ®Google Scholar
• Carosella ED, Moreau P, Lemaoult J, et al. HLA-G: from biology to clinical benefits. Trends Immunol. 2008;29(3):125–132.
   PubMed Web of Science ®Google Scholar
• Fukushima Y, Oshika Y, Nakamura M, et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med. 1998;2(3):349–351.
   PubMed Web of Science ®Google Scholar
• Cao MYS, Liu J, Ye SR, et al. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011;78(2):120–128.
   PubMed Web of Science ®Google Scholar
• Pistoia V, Morandi F, Wang X, et al. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol. 2007;17(6):469–479.
   PubMed Web of Science ®Google Scholar
• Reimers MSEC, Putter H, Morreau H, et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer. 2014;14:486.
   PubMed Web of Science ®Google Scholar
• Ye SR, Yang H, Li K, et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20(3):375–383.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11(2):119–130.
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–1362.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275.
   PubMed Web of Science ®Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–2009.
   PubMed Web of Science ®Google Scholar
• Nizar S, Meyer B, Galustian C, et al. T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta. 2010;1806(1):7–17.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226–230.
   PubMed Web of Science ®Google Scholar
• Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev. 2014;33(4):1025–1041.
   PubMed Web of Science ®Google Scholar
• Vlad C, Kubelac P, Fetica B, et al. The prognostic value of FOXP3+ T regulatory cells in colorectal cancer. J Buon. 2015;20(1):114–119.
   PubMed Web of Science ®Google Scholar
• Xu W, Liu H, Song J, et al. The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer. J Cancer Res Clin Oncol. 2013;139(11):1845–1852.
   PubMed Web of Science ®Google Scholar
• Ling A, Edin S, Wikberg ML, et al. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–2559.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186–192.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol. 2014;31(8):82.
   PubMed Web of Science ®Google Scholar
• Chaput N, Louafi S, Bardier A, et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut. 2009;58(4):520–529.
   PubMed Web of Science ®Google Scholar
• OuYang LY, Wu XJ, Ye SB, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med. 2015;13:47.
   PubMed Web of Science ®Google Scholar
• Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm. 2015;2015:159269.
   PubMed Web of Science ®Google Scholar
• Martin F, Apetoh L, Ghiringhelli F. Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy. 2012;4(1):43–57.
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–795.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70(5):325–330.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008;180(4):2011–2017.
   PubMed Web of Science ®Google Scholar
• Herrera M, Herrera A, Dominguez G, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104(4):437–444.
   PubMed Web of Science ®Google Scholar
• Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. Plos One. 2012;7(10):e47045.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1(8):1223–1225.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548.
   PubMed Web of Science ®Google Scholar
• Hua D, Sun J, Mao Y, et al. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol. 2012;18(9):971–978.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. Plos One. 2013;8(10):e76012.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462–468.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405–413.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787–1796.
   PubMed Web of Science ®Google Scholar
• de Kruijf EM, van Nes JG, Sajet A, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res. 2010;16(4):1272–1280.
   PubMed Web of Science ®Google Scholar